By a News Reporter-Staff News Editor at Journal of Technology -- Sagentia, a global technology and product development company, has been hired by SetPoint Medical to work on the development of the programming interface for a neuromodulation device. The device aims to provide patients with a lower risk and lower cost alternative to immunosuppressive drugs for the treatment of chronic inflammatory diseases.
SetPoint Medical, a Californian-based biomedical technology company that received $27m in financing in August this year and was named by Fierce Medical Devices as one of its '2013 Fierce 15 Device & Diagnostic Companies', is developing a novel, proprietary bioelectronics medicine platform to treat a variety of inflammation-mediated autoimmune diseases as a safe and effective alternative to using drugs. The therapy consists of three core components: an implanted MicroRegulator, a charger unit that charges the MicroRegulator and an "RxPad" iPad prescription application which sets the dose and frequency of the therapy. The implantable MicroRegulator stimulates the vagus nerve, activating the body's natural inflammatory reflex to produce a potent systemic anti-inflammatory effect and resulting in dampened inflammation and improved clinical signs and symptoms.
Sagentia has been brought into the project to develop the iPad App, and to advise on the RF and Bluetooth Low Energy interfaces within the system. Sagentia will develop the app according to the applicable medical device standards in line with the recent guidelines released by the FDA.
Keywords for this news article include: Therapy, Sagentia, Technology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC